Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) - Pipeline Review, H2 2018 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Sep 19, 2018--The “Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) - Pipeline Review, H2 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.
Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) pipeline Target constitutes close to 14 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Preclinical and Discovery stages are 7 and 4 respectively.
ScopeThe report provides a snapshot of the global therapeutic landscape for Myc Proto Oncogene Protein The report reviews Myc Proto Oncogene Protein targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities The report reviews key players involved in Myc Proto Oncogene Protein targeted therapeutics and enlists all their major and minor projects The report assesses Myc Proto Oncogene Protein targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type The report summarizes all the dormant and discontinued pipeline projects The report reviews latest news and deals related to Myc Proto Oncogene Protein targeted therapeutics
Companies FeaturedPeptomyc SL Phylogica Ltd. Sorrento Therapeutics Inc.
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/zktfm7/myc_proto?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180919005360/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Oncology Drugs
INDUSTRY KEYWORD: HEALTH ONCOLOGY PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 09/19/2018 07:25 AM/DISC: 09/19/2018 07:25 AM